CvergenX

CvergenX is a genomic information company that provides decision support for radiation oncologists by developing and commercializing genomic technologies to optimize and personalize radiation therapy prescription doses, as well as identify new compounds that may improve clinical outcomes when combined with radiation therapy. The company's Precision Genomic Radiation Therapy platform (pGRT™) is a clinically validated decision support tool that incorporates genomics into radiation therapy planning using a mathematical rather than empirical approach. The company’s patented Radiation Sensitivity Index (RSI) and Genomic Adjusted Radiation Dose (GARD) were co-developed with the Moffitt Cancer Center.